Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
The article is devoted to topical issues of management of patients with pulmonary arterial hypertension and strategies for switching to riociguat therapy in patients with insufficient clinical response against the background of phosphodiesterase type 5 (PDE-5) inhibitors. The role of the NO metaboli...
Main Author: | E. V. Filippov |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2020-12-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2342 |
Similar Items
-
The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01) -
Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
by: Mihalek AD, et al.
Published: (2022-10-01) -
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01) -
Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension
by: Erin M. Schikowski, et al.
Published: (2022-11-01) -
Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results
by: A A Shmalts, et al.
Published: (2018-06-01)